Ubiquitination/ Proteasome


Once the substrate protein is labeled, proteasome will bind to a polyubiquitin chain, allowing the degradation of the labeled protein. The polyubiquitinated target protein is then recognized and degraded by the 26S proteasome. Deubiquitinating enzymes (DUBs) reverse the process of ubiquitination by removing ubiquitin from its substrate protein. Dysregulation of the ubiquitin-proteasome system has been linked to cancer, diabetes, cardiovascular and neurodegenerative diseases etc.
-
A4010 Salinosporamide A (NPI-0052, Marizomib)Target: ProteasomeSummary: 20S proteasome inhibitor -
A2612 MG-1151 CitationTarget: ProteasomeSummary: Potent reversible proteasome inhibitor -
A1900 PSISummary: Proteasome inhibitor -
A1933 Carfilzomib (PR-171)10 CitationTarget: ProteasomeSummary: Proteasome inhibitor, epoxomicin analog -
A1934 Oprozomib (ONX-0912)5 CitationSummary: Proteasome inhibitor -
A8163 AM 1142 CitationTarget: ProteasomeSummary: 20S proteasome inhibitor -
A3823 SJB2-043Target: USPSummary: USP1 inhibitor -
A3920 Vinblastine sulfate2 CitationSummary: Anti-mitotic agent -
A9984 Thalidomide-O-amido-C4-NH2 TFASummary: A synthetic E3 ligand-Linker conjugate -
BA7375 BI8622Summary: BI8622 is a ubiquitin ligase-specific antagonist.
